Latest Financials News

Daly Resources has posted a $352,743 loss for FY2025 amid aggressive expansion of its exploration portfolio, including the acquisition of the Huckitta and North Batten projects. The company is gearing up for a $10 million IPO in 2026 to fund its base metals and fluorite exploration ambitions.

Ryder Capital Limited has launched a fresh on-market buy-back program targeting up to 8 million ordinary shares, extending its capital management strategy through mid-2027 without requiring shareholder approval.

Ballymore Resources has secured $5.2 million through an oversubscribed capital raise, boosting its capacity to fast-track exploration across multiple Queensland projects.

Adherium Limited secured shareholder approval for all resolutions at its June 19, 2026 Extraordinary General Meeting, including a pivotal 1-for-100 share consolidation and approvals tied to recent capital raises and director participation.

Aeris Resources has received Supreme Court approval to acquire Peel Mining, adding significant copper resources to its Tritton operations and setting the stage for long-life production growth.

Dotz Nano has secured A$3.3 million through a private placement, backing its next phase of production scale-up and customer engagement under incoming CEO Nati Harpaz.

Reef Casino Trust projects a 6.83 cents per unit distribution for the first half of 2026, reflecting steady profitability amid ongoing takeover bid conditions.

PhosCo Ltd has received A$1.1 million from the European Bank for Reconstruction and Development and an additional A$0.6 million from early option exercises, strengthening its cash position ahead of a pivotal updated scoping study for its Gasaat Phosphate Project.

Acrow Limited has secured $70 million through a fully underwritten two-tranche placement to acquire Ausgroup Industrial Services and Preston SuperDeck, boosting its FY27 revenue and EBITDA guidance significantly.

Cynata Therapeutics (ASX: CYP) has had its trading suspension lifted immediately following the publication of results from its Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease clinical trials.

BOA Resources Ltd has voluntarily suspended trading of its shares on the ASX pending a potential acquisition announcement, with the suspension expected to last up to five trading days.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.